Advertisement
The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.

Priorities for pulmonary hypertension research: A James Lind Alliance priority setting partnership

Published:October 01, 2022DOI:https://doi.org/10.1016/j.healun.2022.09.015
      Pulmonary hypertension (PH) is a rare condition associated with significant morbidity and mortality. The priorities for future research in PH according to patients, caregivers, and clinicians have not been established. We performed a James Lind Alliance priority setting partnership in Canada. An initial survey of 249 respondents (76% patients and/or caregivers, 12.5% clinicians) generated 1588 questions, which were combined into 187 summary questions. An evidence check identified 352 systematic reviews and guidelines which were mapped to the summary questions, which determined that 157 summary questions were unanswered by existing research. An interim prioritisation survey (240 respondents, 66% patients and/or caregivers, 18% clinicians) asked respondents to choose which of the 157 summary questions were among the 30-40 most important. In a final workshop patients, caregivers, and clinicians discussed and ranked the top 25 questions from the interim survey to identify the Top 10 PH research priorities. These results will inform researchers and funding bodies about patient, caregiver, and clinician priorities for future research on PH.

      KEYWORDS

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Simonneau G
        • Montani D
        • Celermajer DS
        • et al.
        Hemodynamic definitions and updated clinical classification of pulmonary hypertension.
        Eur Respir J. 2019; 531801913https://doi.org/10.1183/13993003.01913-2018
        • Hassoun PM.
        Pulmonary Arterial Hypertension.
        N Engl J Med. 2021; 385: 2361-2376https://doi.org/10.1056/NEJMra2000348
      1. Canadian Institutes of Health Research. Canada's Strategy for Patient-Oriented Research: Improving health outcomes through evidence-informed care. 2011. Available at: https://cihr-irsc.gc.ca/e/44000.html. (accessed 11 May 2022).

      2. JLA Guidebook | James Lind Alliance. Available at: https://www.jla.nihr.ac.uk/jla-guidebook. (accessed 8 Mar 2022).

        • Humbert M
        • Guignabert C
        • Bonnet S
        • et al.
        Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.
        Eur Respir J. 2019; 531801887https://doi.org/10.1183/13993003.01887-2018
        • Savale L
        • Guignabert C
        • Weatherald J
        • et al.
        Precision medicine and personalizing therapy in pulmonary hypertension: seeing the light from the dawn of a new era.
        Eur Respir Rev. 2018; 27180004https://doi.org/10.1183/16000617.0004-2018
        • Lahm T
        • Douglas IS
        • Archer SL
        • et al.
        Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.
        Am J Respir Crit Care Med. 2018; 198: e15-e43https://doi.org/10.1164/rccm.201806-1160ST